

Wednesday 3 October 2007

Introductions and overview ? Educational objectives of the programme - David Gerrett (UK)

Download PDF ^[1]

Setting the scene ? the questions that need to be answered when selecting a biological - Wim Jiskoot (The Netherlands)

Download PDF^[2]

Case study: what can go wrong? - Huub Schellekens (The Netherlands)

Download PDF^[3]

Molecular biotechnology - Harald Sitte (Austria)

Download PDF^[4]

Structure and analysis of recombinant proteins - Wim Jiskoot (The Netherlands)

Download PDF^[5]

Production and downstream processing/purification - Wim Jiskoot (The Netherlands)

Download PDF^[6]

Formulation - Bruno Gander (Switzerland)

Download PDF^[7]

Route of administration, including biopharmaceutical considerations - Harald Sitte (Austria)

Download PDF^[8]

PK/PD of peptide and protein drugs - Harald Sitte (Austria)

Download PDF^[9]

Drug design - Harald Sitte (Austria)

Download PDF^[10]

What have we learned? How will we teach it? What will we do tomorrow? - David Gerrett (UK)

Download PDF^[11]

Thursday 4 October 2007

Welcome and recap on the day's agenda - David Gerrett (UK)

Download PDF [\[12\]](#)

Safety of biological pharmaceuticals - Huub Schellekens (The Netherlands)

Download PDF [\[13\]](#)

Basic methodologies in biotechnology - Harald Sitte (Austria)

Download PDF [\[14\]](#)

Clinical trials - David Gerrett (UK)

Download PDF [\[15\]](#)

Handling in the pharmacy

Download PDF [\[16\]](#) - Roger Tredree (UK)

Download PDF [\[17\]](#) - Friedrich Möll (Switzerland)

Biosimilars - Huub Schellekens (The Netherlands)

Download PDF [\[18\]](#)

Biopharmaceuticals and shifting paradigms - Daan Crommelin (The Netherlands)

Download PDF [\[19\]](#)

Clinical governance and the role of the hospital pharmacist - David Gerrett (UK)

Download PDF [\[20\]](#)

Friday 5 October 2007

Welcome and recap on the day's agenda - David Gerrett (UK)

Download PDF [\[21\]](#)

Biopharmaceuticals for immunological intervention

Download PDF [\[22\]](#) - Wim Jiskoot (The Netherlands)

Download PDF [\[23\]](#) - Huub Schellekens (The Netherlands)

Pharmacoeconomics - David Gerrett (UK)

Download PDF [\[24\]](#)

Links

- [1] [https://www.eahp.eu/sites/default/files/files/01_01_Introduction_and_overview_Gerrett_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/01_01_Introduction_and_overview_Gerrett_(NXP).pdf)
- [2] [https://www.eahp.eu/sites/default/files/files/01_02_Setting_the_scene_Jiskoot_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/01_02_Setting_the_scene_Jiskoot_(NXP).pdf)
- [3] [https://www.eahp.eu/sites/default/files/files/01_03_Case_study_Schellekens_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/01_03_Case_study_Schellekens_(NXP).pdf)
- [4] [https://www.eahp.eu/sites/default/files/files/01_04_Molecular_biotechnology_Sitte_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/01_04_Molecular_biotechnology_Sitte_(NXP).pdf)
- [5] https://www.eahp.eu/sites/default/files/files/01_05_Structure_%26_analysis_of_recombinant_proteins_Jiskoot.pdf
- [6] https://www.eahp.eu/sites/default/files/files/01_06_Production_%26_downstream_processing_Jiskoot.pdf
- [7] [https://www.eahp.eu/sites/default/files/files/01_07_Formulation_Gander_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/01_07_Formulation_Gander_(NXP).pdf)
- [8] [https://www.eahp.eu/sites/default/files/files/01_08_Route_of_administration_Sitte_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/01_08_Route_of_administration_Sitte_(NXP).pdf)
- [9] https://www.eahp.eu/sites/default/files/files/01_09_PK-PD_of_peptide_%26_protein_drugs_Sitte.pdf
- [10] [https://www.eahp.eu/sites/default/files/files/01_10_Drug_design_Sitte_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/01_10_Drug_design_Sitte_(NXP).pdf)
- [11] [https://www.eahp.eu/sites/default/files/files/01_11_What_have_we_learned_day1_Gerrett_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/01_11_What_have_we_learned_day1_Gerrett_(NXP).pdf)
- [12] [https://www.eahp.eu/sites/default/files/files/02_01_Recap_on_the_days_agenda_Gerrett_\(NXP\).ppt](https://www.eahp.eu/sites/default/files/files/02_01_Recap_on_the_days_agenda_Gerrett_(NXP).ppt)
- [13] [https://www.eahp.eu/sites/default/files/files/02_02_Safety_of_biological_pharmaceuticals_Schellekens_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/02_02_Safety_of_biological_pharmaceuticals_Schellekens_(NXP).pdf)
- [14] [https://www.eahp.eu/sites/default/files/files/02_03_Basic_methodologies_in_biotechnology_Sitte_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/02_03_Basic_methodologies_in_biotechnology_Sitte_(NXP).pdf)
- [15] [https://www.eahp.eu/sites/default/files/files/02_04_Clinical_trials_Gerrett_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/02_04_Clinical_trials_Gerrett_(NXP).pdf)
- [16] [https://www.eahp.eu/sites/default/files/files/02_05a_Handling_in_the_pharmacy_Tredree_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/02_05a_Handling_in_the_pharmacy_Tredree_(NXP).pdf)
- [17] [https://www.eahp.eu/sites/default/files/files/02_05b_Handling_in_the_pharmacy_M%C3%B6ll_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/02_05b_Handling_in_the_pharmacy_M%C3%B6ll_(NXP).pdf)
- [18] [https://www.eahp.eu/sites/default/files/files/02_06_Biosimilars_Schellekens_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/02_06_Biosimilars_Schellekens_(NXP).pdf)
- [19] [https://www.eahp.eu/sites/default/files/files/02_07_Biopharmaceuticals_%26_shifting_paradigms_Crommelin_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/02_07_Biopharmaceuticals_%26_shifting_paradigms_Crommelin_(NXP).pdf)
- [20] [https://www.eahp.eu/sites/default/files/files/02_08_Clinical_governance_Gerrett_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/02_08_Clinical_governance_Gerrett_(NXP).pdf)
- [21] [https://www.eahp.eu/sites/default/files/files/03_01_Recap_on_the_days_agenda_day3_Gerrett_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/03_01_Recap_on_the_days_agenda_day3_Gerrett_(NXP).pdf)
- [22] [https://www.eahp.eu/sites/default/files/files/03_02a_Biopharmaceuticals_for_immunological_intervention_Jiskoot_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/03_02a_Biopharmaceuticals_for_immunological_intervention_Jiskoot_(NXP).pdf)
- [23] [https://www.eahp.eu/sites/default/files/files/03_02b_Biopharmaceuticals_for_immunological_intervention_Schellekens_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/03_02b_Biopharmaceuticals_for_immunological_intervention_Schellekens_(NXP).pdf)
- [24] [https://www.eahp.eu/sites/default/files/files/03_03_Pharmacoeconomics_Gerrett_\(NXP\).pdf](https://www.eahp.eu/sites/default/files/files/03_03_Pharmacoeconomics_Gerrett_(NXP).pdf)